Johnson & Johnson (JNJ)vsSi-Bone Inc (SIBN)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
SIBN
Si-Bone Inc
$21.83
+1.82%
HEALTHCARE · Cap: $945.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 46404% more annual revenue ($99.33B vs $213.60M). JNJ leads profitability with a 16.2% profit margin vs -6.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SIBN
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Margin of Safety
+43.6%
Fair Value
$26.55
Current Price
$21.83
$4.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Conservative balance sheet, low leverage
15.2% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -8.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : SIBN
The strongest argument for SIBN centers on Debt/Equity, Revenue Growth. Revenue growth of 15.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : SIBN
The primary concerns for SIBN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SIBN is a growth play — different risk/reward profiles.
SIBN carries more volatility with a beta of 0.66 — expect wider price swings.
SIBN is growing revenue faster at 15.2% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 27/100), backed by strong 16.2% margins. SIBN offers better value entry with a 43.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Si-Bone Inc
HEALTHCARE · MEDICAL DEVICES · USA
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and internationally. The company is headquartered in Santa Clara, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?